N-alkyl-2-(2-undecyl-1H-benzimidazol-1-yl)acetamides as antiproliferative agents with special application for invasive breast cancer, design, synthesis,in vitro,and computational studies

نویسندگان
doi
10.48309/jmpcr.2026.566651.1945
چکیده

A series of 10 new N-alkyl-2-(2-undecyl-1H-benzimidazol-1-yl) acetamides were prepared from 2-(2-undecyl-1H-benzimidazol-1-yl)acetohydrazide via azide coupling method with a variety of amines. The compounds were tested for their antiproliferative activity on five cell lines; A549, MDA-MB231, MCF-7, U87, and HEK293 to elucidate their preferential activity on invasive cancer cells. The results showed that most compounds exerted enhanced activity against MDA-MB231 compared to other cell lines. Compounds 7h, 7i, 7a, and 7j showed the highest inhibition with IC50 of 40.3±5.5, 72.7±7.1, 105.1±3.8, and 172.5±5.3 μM against MDA-MB 231, respectively. Compound 7i showed the broadest spectrum of activity against all tested cell lines (IC50 of 61.4±1.77, 72.7±7.1, 38.8±5.3, and 43.9±1.8 for A549, MDA-MB 231, MCF7, and U87 respectively). A notable finding was the selectivity of cancer cells, wherein compounds 7a, 7h, and 7i exhibited the highest selectivity towards MDA-MB231, with selectivity indices of 1.69, 4.31, and 1.72, respectively, compared to normal cells (HEK 293). In silico mechanistic studies corroborated a cathepsin K-mediated activity, with compound 7i achieving the most favorable docking score of -7.126. Molecular dynamics (MD) simulations indicated that 7i maintained stability within the binding pocket, exhibiting minimal fluctuations. The lipophilicity efficiency (LLE) calculations demonstrated that optimal potency was frequently associated with moderate lipophilicity, as seen in compound 7i. This study introduces a hit identification protocol in which novel benzimidazole derivatives demonstrated significant antiproliferative activity, particularly against invasive breast cancer cell lines. Initial in silico analyses identified cathepsin K as a potential target for subsequent rational lead development.